chlorpromazine has been researched along with Weight Gain in 15 studies
Chlorpromazine: The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking DOPAMINE RECEPTORS. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.
chlorpromazine : A substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropanamine moiety.
Weight Gain: Increase in BODY WEIGHT over existing weight.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Therefore, we conducted a 12-week double-blind comparison study to assess the efficacy and tolerability of clozapine and chlorpromazine in a group of elderly inpatients with chronic schizophrenia." | 9.09 | The efficacy and safety of clozapine versus chlorpromazine in geriatric schizophrenia. ( Eisenstein, N; Engelhart, C; Howanitz, E; Losonczy, MF; Pardo, M; Smelson, DA; Stern, RG, 1999) |
| "A 6-week, double-blind, randomized, multicentre, parallel-group study was conducted to compare the efficacy of quetiapine ('Seroquel') (n=101) with that of chlorpromazine (n=100) in hospitalized patients with acute exacerbation of subchronic or chronic schizophrenia, or schizophreniform disorder." | 9.08 | A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. ( Link, CG; Peuskens, J, 1997) |
| "Seizures were induced in female Wistar albino rats at either 35 or 55 days of age with a single systemic injection of lithium (3 mEq/kg) and pilocarpine (30 mg/kg); the rats were then treated with the atypical neuroleptic acepromazine (25 mg/kg)." | 7.73 | Extreme obesity in female rats following prepuberal induction of lithium-pilocarpine seizures and a single injection of acepromazine. ( Persinger, MA; St-Pierre, LS, 2005) |
| " Therefore, we conducted a 12-week double-blind comparison study to assess the efficacy and tolerability of clozapine and chlorpromazine in a group of elderly inpatients with chronic schizophrenia." | 5.09 | The efficacy and safety of clozapine versus chlorpromazine in geriatric schizophrenia. ( Eisenstein, N; Engelhart, C; Howanitz, E; Losonczy, MF; Pardo, M; Smelson, DA; Stern, RG, 1999) |
| "A 6-week, double-blind, randomized, multicentre, parallel-group study was conducted to compare the efficacy of quetiapine ('Seroquel') (n=101) with that of chlorpromazine (n=100) in hospitalized patients with acute exacerbation of subchronic or chronic schizophrenia, or schizophreniform disorder." | 5.08 | A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. ( Link, CG; Peuskens, J, 1997) |
| "A 26-year-old woman with schizophrenia gained 7 kg over the course of 1 year after starting treatment with olanzapine." | 3.73 | Body weight gain induced by a newer antipsychotic agent reversed as negative symptoms improved. ( Koga, M; Nakayama, K, 2005) |
| "Seizures were induced in female Wistar albino rats at either 35 or 55 days of age with a single systemic injection of lithium (3 mEq/kg) and pilocarpine (30 mg/kg); the rats were then treated with the atypical neuroleptic acepromazine (25 mg/kg)." | 3.73 | Extreme obesity in female rats following prepuberal induction of lithium-pilocarpine seizures and a single injection of acepromazine. ( Persinger, MA; St-Pierre, LS, 2005) |
| "Polydipsia was the most prevalent (24, 60." | 1.51 | Adverse drug reactions experienced by out-patients taking chlorpromazine or haloperidol at Zomba Mental Hospital, Malawi. ( Chikowe, I; Domingo, M; Kampira, E; Mafuta, C; Mwakaswaya, V; Parveen, S, 2019) |
| "In order to examine potential ovarian toxicity in 2 weeks or 4 weeks repeated-dose studies and a fertility study, chlorpromazine hydrochloride (CPZ) was administered orally to Crl:CD(SD) female rats at dosage levels of 0, 3, 10 and 30 mg/kg/day." | 1.35 | Collaborative work on evaluation of ovarian toxicity. 16) Effects of 2 or 4 weeks repeated dose studies and fertility study of Chlorpromazine hydrochloride in rats. ( Awasaki, N; Chatani, F; Hikawa, K; Izumi, Y; Minagi, T; Watanabe, T, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.67) | 18.7374 |
| 1990's | 3 (20.00) | 18.2507 |
| 2000's | 10 (66.67) | 29.6817 |
| 2010's | 1 (6.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kroeze, WK | 1 |
| Hufeisen, SJ | 1 |
| Popadak, BA | 1 |
| Renock, SM | 1 |
| Steinberg, S | 1 |
| Ernsberger, P | 1 |
| Jayathilake, K | 1 |
| Meltzer, HY | 1 |
| Roth, BL | 1 |
| Lange, JH | 1 |
| Reinders, JH | 1 |
| Tolboom, JT | 1 |
| Glennon, JC | 1 |
| Coolen, HK | 1 |
| Kruse, CG | 1 |
| Chikowe, I | 1 |
| Domingo, M | 1 |
| Mwakaswaya, V | 1 |
| Parveen, S | 1 |
| Mafuta, C | 1 |
| Kampira, E | 1 |
| Izumi, Y | 1 |
| Watanabe, T | 1 |
| Awasaki, N | 1 |
| Hikawa, K | 1 |
| Minagi, T | 1 |
| Chatani, F | 1 |
| Zhang, ZJ | 2 |
| Yao, ZJ | 2 |
| Zhang, XB | 2 |
| Chen, JF | 1 |
| Sun, J | 2 |
| Yao, H | 1 |
| Hou, G | 1 |
| Koponen, H | 1 |
| Larmo, I | 1 |
| Koga, M | 1 |
| Nakayama, K | 1 |
| St-Pierre, LS | 1 |
| Persinger, MA | 1 |
| Mou, XD | 1 |
| Liu, W | 1 |
| Zhang, XR | 1 |
| Shi, JB | 1 |
| Amamoto, T | 1 |
| Kumai, T | 1 |
| Nakaya, S | 1 |
| Matsumoto, N | 1 |
| Tsuzuki, Y | 1 |
| Kobayashi, S | 1 |
| Winsberg, B | 1 |
| Usubiaga, H | 1 |
| Cooper, T | 1 |
| Jordan, S | 1 |
| Torrance, C | 1 |
| Peuskens, J | 1 |
| Link, CG | 1 |
| Howanitz, E | 1 |
| Pardo, M | 1 |
| Smelson, DA | 1 |
| Engelhart, C | 1 |
| Eisenstein, N | 1 |
| Stern, RG | 1 |
| Losonczy, MF | 1 |
| Vieweg, WV | 1 |
| Godleski, LS | 1 |
| Mitchell, M | 1 |
| Hundley, PL | 1 |
| Yank, GR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Orally-Disintegrating vs. Regular Olanzapine Tablets: Effects on Weight and GI Hormones[NCT00384332] | Phase 4 | 20 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Montgomery Asberg Depression Rating Scale (MADRS) total score. Construct: Depression severity. Scores below represent mean change scores, endpoint minus baseline. Minimum total score: 0 (no depression). Maximum total score: 60 (severe depression). Lower (more negative) scores indicate a better outcome. There are no subscales. (NCT00384332)
Timeframe: 10 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Arm 1 | -15.5 |
| Arm 2 | -15.5 |
Change in weight from baseline to endpoint in kilograms. Reported as weight in Kilograms at Baseline, Weeks 1, 4, 6, and 8 (NCT00384332)
Timeframe: 10 weeks
| Intervention | kilograms (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Week 1 | Week 4 | Week 6 | Week 8 | |
| Arm 1- ODT | 76.0 | 77.4 | 77.8 | 78.9 | 79.1 |
| Arm 2- SOT | 76.1 | 77.6 | 78.3 | 79.4 | 80.1 |
3 trials available for chlorpromazine and Weight Gain
| Article | Year |
|---|---|
Ghrelin and leptin response to oral glucose challenge among antipsychotic drug-treated children.
Topics: Administration, Oral; Adolescent; Age Factors; Analysis of Variance; Antipsychotic Agents; Aripipraz | 2007 |
A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Chlorpromazine; Dibenzothiazepines; Double-Blin | 1997 |
The efficacy and safety of clozapine versus chlorpromazine in geriatric schizophrenia.
Topics: Age Factors; Aged; Agranulocytosis; Antipsychotic Agents; Chlorpromazine; Clozapine; Double-Blind Me | 1999 |
12 other studies available for chlorpromazine and Weight Gain
| Article | Year |
|---|---|
H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.
Topics: Animals; Antipsychotic Agents; Discriminant Analysis; Drug Evaluation, Preclinical; Forecasting; Hum | 2003 |
Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzoxazines; Biogenic Monoamines; Humans; Hyperprolac | 2007 |
Adverse drug reactions experienced by out-patients taking chlorpromazine or haloperidol at Zomba Mental Hospital, Malawi.
Topics: Adolescent; Adult; Antipsychotic Agents; Chlorpromazine; Cross-Sectional Studies; Erectile Dysfuncti | 2019 |
Collaborative work on evaluation of ovarian toxicity. 16) Effects of 2 or 4 weeks repeated dose studies and fertility study of Chlorpromazine hydrochloride in rats.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Blepharoptosis; Chlorpromazine; Drug Administra | 2009 |
No association of antipsychotic agent-induced weight gain with a DA receptor gene polymorphism and therapeutic response.
Topics: Adult; Antipsychotic Agents; Body Mass Index; Chlorpromazine; Female; Gene Frequency; Genotype; Huma | 2003 |
Reversal of antipsychotic-induced weight gain during quetiapine treatment.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Brain Injuries; Chlorpromazine; Dibenzothiazepines; Hu | 2003 |
Body weight gain induced by a newer antipsychotic agent reversed as negative symptoms improved.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Diet; Exercise; Female; Haloperidol; H | 2005 |
Extreme obesity in female rats following prepuberal induction of lithium-pilocarpine seizures and a single injection of acepromazine.
Topics: Acepromazine; Animals; Body Weight; Chlorpromazine; Convulsants; Dopamine Antagonists; Female; Lithi | 2005 |
[No association of -1438G/A polymorphism in promoter region of 5-HT2A receptor gene with antipsychotic agent-induced weight gain].
Topics: Adult; Antipsychotic Agents; Chlorpromazine; Female; Gene Frequency; Genotype; Humans; Male; Polymer | 2005 |
The elucidation of the mechanism of weight gain and glucose tolerance abnormalities induced by chlorpromazine.
Topics: Adiponectin; Animals; Antipsychotic Agents; Blood Glucose; Chlorpromazine; Glucose Tolerance Test; I | 2006 |
Bionursing: how drugs can cause weight gain.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Appetite; Body Weight; Chlorpromazine; Female; Humans; | 1996 |
Abnormal diurnal weight gain among chronically psychotic patients contrasted with acutely psychotic patients and normals.
Topics: Adult; Affective Disorders, Psychotic; Blood Pressure; Chlorpromazine; Circadian Rhythm; Drinking Be | 1989 |